• Citer

Drotrecogin alfa (activated) in patients with severe sepsis presenting with purpura fulminans, meningitis, or meningococcal disease: a retrospective analysis of patients enrolled in recent clinical studies.

par Vincent, Jean Louis ;Nadel, Simon;Kutsogiannis, Demetrios J;Gibney, R T Noel;Yan, S Betty;Wyss, Virginia L;Bailey, Joan;Mitchell, Carol L;Sarwat, Samiha;Shinall, Stephen M;Janes, Jonathan
Référence Critical care, 9, 4, page (R331-R343)
Publication Publié, 2005-08

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Résumé :

We report data from adult and pediatric patients with severe sepsis from studies evaluating drotrecogin alfa (activated) (DrotAA) and presenting with purpura fulminans (PF), meningitis (MEN), or meningococcal disease (MD) (PF/MEN/MD). Such conditions may be associated with an increased bleeding risk but occur in a relatively small proportion of patients presenting with severe sepsis; pooling data across clinical trials provides an opportunity for improving the characterization of outcomes.